The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Direct Renin Inhibitors (DRIs) Market Research Report 2024
Synopsis
Direct renin inhibition is a new means for blocking the renin–angiotensin system at the rate-limiting step of the cascade of events triggered by renin release—the interaction of renin with its physiological substrate angiotensinogen.
The global Direct Renin Inhibitors (DRIs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Direct Renin Inhibitors (DRIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Direct Renin Inhibitors (DRIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Direct Renin Inhibitors (DRIs) include Noden Pharma, LGM Pharma and Cayman, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Direct Renin Inhibitors (DRIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Renin Inhibitors (DRIs).
Report Scope
The Direct Renin Inhibitors (DRIs) market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Direct Renin Inhibitors (DRIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct Renin Inhibitors (DRIs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Noden Pharma
LGM Pharma
Cayman
Segment by Type
Aliskiren
Remikiren
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Direct Renin Inhibitors (DRIs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Direct Renin Inhibitors (DRIs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Direct renin inhibition is a new means for blocking the renin–angiotensin system at the rate-limiting step of the cascade of events triggered by renin release—the interaction of renin with its physiological substrate angiotensinogen.
The global Direct Renin Inhibitors (DRIs) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Direct Renin Inhibitors (DRIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Direct Renin Inhibitors (DRIs) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Direct Renin Inhibitors (DRIs) include Noden Pharma, LGM Pharma and Cayman, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Direct Renin Inhibitors (DRIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Renin Inhibitors (DRIs).
Report Scope
The Direct Renin Inhibitors (DRIs) market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Direct Renin Inhibitors (DRIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct Renin Inhibitors (DRIs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Noden Pharma
LGM Pharma
Cayman
Segment by Type
Aliskiren
Remikiren
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Direct Renin Inhibitors (DRIs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Direct Renin Inhibitors (DRIs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Direct Renin Inhibitors (DRIs) Market Overview
1.1 Product Overview and Scope of Direct Renin Inhibitors (DRIs)
1.2 Direct Renin Inhibitors (DRIs) Segment by Type
1.2.1 Global Direct Renin Inhibitors (DRIs) Market Value Comparison by Type (2024-2030)
1.2.2 Aliskiren
1.2.3 Remikiren
1.2.4 Others
1.3 Direct Renin Inhibitors (DRIs) Segment by Application
1.3.1 Global Direct Renin Inhibitors (DRIs) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Direct Renin Inhibitors (DRIs) Market Size Estimates and Forecasts
1.4.1 Global Direct Renin Inhibitors (DRIs) Revenue 2019-2030
1.4.2 Global Direct Renin Inhibitors (DRIs) Sales 2019-2030
1.4.3 Global Direct Renin Inhibitors (DRIs) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Direct Renin Inhibitors (DRIs) Market Competition by Manufacturers
2.1 Global Direct Renin Inhibitors (DRIs) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Direct Renin Inhibitors (DRIs) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Direct Renin Inhibitors (DRIs) Average Price by Manufacturers (2019-2024)
2.4 Global Direct Renin Inhibitors (DRIs) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Direct Renin Inhibitors (DRIs), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Direct Renin Inhibitors (DRIs), Product Type & Application
2.7 Direct Renin Inhibitors (DRIs) Market Competitive Situation and Trends
2.7.1 Direct Renin Inhibitors (DRIs) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Direct Renin Inhibitors (DRIs) Players Market Share by Revenue
2.7.3 Global Direct Renin Inhibitors (DRIs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Direct Renin Inhibitors (DRIs) Retrospective Market Scenario by Region
3.1 Global Direct Renin Inhibitors (DRIs) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Direct Renin Inhibitors (DRIs) Global Direct Renin Inhibitors (DRIs) Sales by Region: 2019-2030
3.2.1 Global Direct Renin Inhibitors (DRIs) Sales by Region: 2019-2024
3.2.2 Global Direct Renin Inhibitors (DRIs) Sales by Region: 2025-2030
3.3 Global Direct Renin Inhibitors (DRIs) Global Direct Renin Inhibitors (DRIs) Revenue by Region: 2019-2030
3.3.1 Global Direct Renin Inhibitors (DRIs) Revenue by Region: 2019-2024
3.3.2 Global Direct Renin Inhibitors (DRIs) Revenue by Region: 2025-2030
3.4 North America Direct Renin Inhibitors (DRIs) Market Facts & Figures by Country
3.4.1 North America Direct Renin Inhibitors (DRIs) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Direct Renin Inhibitors (DRIs) Sales by Country (2019-2030)
3.4.3 North America Direct Renin Inhibitors (DRIs) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Direct Renin Inhibitors (DRIs) Market Facts & Figures by Country
3.5.1 Europe Direct Renin Inhibitors (DRIs) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Direct Renin Inhibitors (DRIs) Sales by Country (2019-2030)
3.5.3 Europe Direct Renin Inhibitors (DRIs) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Direct Renin Inhibitors (DRIs) Market Facts & Figures by Country
3.6.1 Asia Pacific Direct Renin Inhibitors (DRIs) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Direct Renin Inhibitors (DRIs) Sales by Country (2019-2030)
3.6.3 Asia Pacific Direct Renin Inhibitors (DRIs) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Direct Renin Inhibitors (DRIs) Market Facts & Figures by Country
3.7.1 Latin America Direct Renin Inhibitors (DRIs) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Direct Renin Inhibitors (DRIs) Sales by Country (2019-2030)
3.7.3 Latin America Direct Renin Inhibitors (DRIs) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Direct Renin Inhibitors (DRIs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Direct Renin Inhibitors (DRIs) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Direct Renin Inhibitors (DRIs) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Direct Renin Inhibitors (DRIs) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Direct Renin Inhibitors (DRIs) Sales by Type (2019-2030)
4.1.1 Global Direct Renin Inhibitors (DRIs) Sales by Type (2019-2024)
4.1.2 Global Direct Renin Inhibitors (DRIs) Sales by Type (2025-2030)
4.1.3 Global Direct Renin Inhibitors (DRIs) Sales Market Share by Type (2019-2030)
4.2 Global Direct Renin Inhibitors (DRIs) Revenue by Type (2019-2030)
4.2.1 Global Direct Renin Inhibitors (DRIs) Revenue by Type (2019-2024)
4.2.2 Global Direct Renin Inhibitors (DRIs) Revenue by Type (2025-2030)
4.2.3 Global Direct Renin Inhibitors (DRIs) Revenue Market Share by Type (2019-2030)
4.3 Global Direct Renin Inhibitors (DRIs) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Direct Renin Inhibitors (DRIs) Sales by Application (2019-2030)
5.1.1 Global Direct Renin Inhibitors (DRIs) Sales by Application (2019-2024)
5.1.2 Global Direct Renin Inhibitors (DRIs) Sales by Application (2025-2030)
5.1.3 Global Direct Renin Inhibitors (DRIs) Sales Market Share by Application (2019-2030)
5.2 Global Direct Renin Inhibitors (DRIs) Revenue by Application (2019-2030)
5.2.1 Global Direct Renin Inhibitors (DRIs) Revenue by Application (2019-2024)
5.2.2 Global Direct Renin Inhibitors (DRIs) Revenue by Application (2025-2030)
5.2.3 Global Direct Renin Inhibitors (DRIs) Revenue Market Share by Application (2019-2030)
5.3 Global Direct Renin Inhibitors (DRIs) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Noden Pharma
6.1.1 Noden Pharma Corporation Information
6.1.2 Noden Pharma Description and Business Overview
6.1.3 Noden Pharma Direct Renin Inhibitors (DRIs) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Noden Pharma Direct Renin Inhibitors (DRIs) Product Portfolio
6.1.5 Noden Pharma Recent Developments/Updates
6.2 LGM Pharma
6.2.1 LGM Pharma Corporation Information
6.2.2 LGM Pharma Description and Business Overview
6.2.3 LGM Pharma Direct Renin Inhibitors (DRIs) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 LGM Pharma Direct Renin Inhibitors (DRIs) Product Portfolio
6.2.5 LGM Pharma Recent Developments/Updates
6.3 Cayman
6.3.1 Cayman Corporation Information
6.3.2 Cayman Description and Business Overview
6.3.3 Cayman Direct Renin Inhibitors (DRIs) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Cayman Direct Renin Inhibitors (DRIs) Product Portfolio
6.3.5 Cayman Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Direct Renin Inhibitors (DRIs) Industry Chain Analysis
7.2 Direct Renin Inhibitors (DRIs) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Direct Renin Inhibitors (DRIs) Production Mode & Process
7.4 Direct Renin Inhibitors (DRIs) Sales and Marketing
7.4.1 Direct Renin Inhibitors (DRIs) Sales Channels
7.4.2 Direct Renin Inhibitors (DRIs) Distributors
7.5 Direct Renin Inhibitors (DRIs) Customers
8 Direct Renin Inhibitors (DRIs) Market Dynamics
8.1 Direct Renin Inhibitors (DRIs) Industry Trends
8.2 Direct Renin Inhibitors (DRIs) Market Drivers
8.3 Direct Renin Inhibitors (DRIs) Market Challenges
8.4 Direct Renin Inhibitors (DRIs) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
